NL-OMON20624尚未招募不适用
ong-term integrity of hematopoiesis in pediatric stem cell transplantation survivors
Prinses Máxima Center for Pediatric Oncology0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Underwent allogeneic HSCT at age =18 yrs
- •-A minimum survival of 5 years after HSCT. In case a patient has received multiple HSCTs, the last HSCT will be used to determine this 5-year minimum.
排除标准
- •-Recipients of a NiCord” HSCT. NiCord is a clinical trial on the safety and efficacy of transplantation of ex vivo expanded cord blood HSCs. As outcome measures of our study overlap with the outcome of this trial, NiCord recipients will be excluded.
- •-Failure of the HSCT recipient and/or their legal representatives to understand the patient information and informed consent form (either due to intellectual disability or to language problems).
研究者
相似试验
招募中
不适用
ong-term integrity of hematopoiesis in pediatric stem cell transplantation survivorsHematopoietic stem cell transplantationbone marrow transplantation1000208610027665NL-OMON54142Prinses Máxima Centrum voor Kinderoncologie375
已完成
不适用
Impact of immature haematopoetic cells on clinical risk stratification of patients with coagulation inhibitor therapycardiolgical, angiological, heart and vascular surgical interventionsDRKS00028143niversitäts-Herzzentrum Freiburg- Bad Krozingen, Campus Bad Krozingen17,835
招募中
不适用
Bonehealth in children and adolescents with hematologic/oncologic diseasescomplete spectrum of paediatric oncologic diseases.chronic haematological diseases (sickle cell, thalassemia)C00-C97D55-D59Malignant neoplasmsHaemolytic anaemiasDRKS00003636Abteilung für Hämatologie und OnkologieKinderklinik IIIUniversitätsklinikum Essen1,000
招募中
不适用
A prospective study of pediatric hereditary hematological disordersPediatric hereditary hematological disordersJPRN-UMIN000037774agoya university1,000
招募中
不适用
Immune cell profiles in the blood in children, adolescents and adults with tuberous sclerosis complex disease and their correlation with organ manifestations and treatment response to immunotherapy with mTOR inhibitorsQ85.1G40Tuberous sclerosisEpilepsyDRKS00022991niversitätsklinikum Münster90